Renal catabolism of advanced glycation end products: The fate of pentosidine
- 1 February 1998
- journal article
- Published by Elsevier in Kidney International
- Vol. 53 (2) , 416-422
- https://doi.org/10.1046/j.1523-1755.1998.00756.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapyKidney International, 1997
- Monocyte/macrophage response to β2-microglobulin modified with advanced glycation end productsKidney International, 1996
- β2-Microglobulin Modified with Advanced Glycation End Products Induces Interleukin-6 from Human Macrophages: Role in the Pathogenesis of Hemodialysis-Associated AmyloidosisBiochemical and Biophysical Research Communications, 1994
- Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.Journal of Clinical Investigation, 1994
- Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.Journal of Clinical Investigation, 1993
- Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.Journal of Clinical Investigation, 1993
- Role of Oxidative Stress in Development of Complications in DiabetesDiabetes, 1991
- Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicityKidney International, 1991
- Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue RemodelingScience, 1988
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988